Section Arrow
Quote
FTRE.NASDAQ
- Fortrea Holdings
Quotes are at least 15-min delayed:2026/07/19 11:29 EDT
Regular Hours
Last
 17.76
-0.16 (-0.89%)
Day High 
18.115 
Prev. Close
17.92 
1-M High
18.34 
Volume 
938.51K 
Bid
17.3
Ask
18.25
Day Low
17.52 
Open
17.73 
1-M Low
14.88 
Market Cap 
1.69B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 17.68 
20-SMA 17.22 
50-SMA 15.95 
52-W High 18.67 
52-W Low 4.57 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.81/1.50
Enterprise Value
2.80B
Balance Sheet
Book Value Per Share
5.56
Cash Flow
Cash Flow Yield
0.13
Income Statement
Total Revenue
2.70B
Operating Revenue Per Share
32.58
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ATAIAtaiBeckley Inc7.22+0.07+0.98%-- 
JSPRJasper Therapeutics0.885+0.111+14.34%-- 
LIMNLiminatus Pharma Inc0.123-0.0247-16.72%-- 
IOVAIovance Biotherapeutics5+0.34+7.30%-- 
RXRXRecursion Pharmaceuticals2.945-0.075-2.48%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.